ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Exploring the role of medicinal plants and nanotechnology in the management of polycystic ovarian syndrome (PCOS): a scoping review.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by heterogeneous symptoms and is commonly managed with conventional medications that often exhibit variable efficacy and undesirable side effects. Given these limitations, nanotechnology, particularly plant-derived metallic nanoparticles, offers novel strategies to enhance phytochemical delivery, stability, and bioavailability. Accordingly, this scoping review synthesizes preclinical evidence (2015-2025) on plant-derived metallic nanoparticles for PCOS, evaluating therapeutic outcomes, safety, and mechanisms. In line with PRISMA-ScR guidance, records were identified from PubMed, Scopus, and ScienceDirect (n = 375), duplicates were removed (n = 51), and 324 records underwent screening. Three hundred twenty records were excluded based on title/abstract screening, and 4 reports were retrieved from databases for eligibility assessment. Together with 1 additional study from Google Scholar, 5 rodent studies were included. Reporting quality and risk of bias were assessed descriptively using selected ARRIVE- and SYRCLE-based domains. Overall, the included studies evaluated cinnamon-derived silver nanoparticles, selenium nanoparticles synthesized using Corchorus olitorius, silver nanoparticles synthesized from aqueous extract of fresh asparagus stems, and silver nanoparticles prepared using fenugreek aqueous extract. Across the included studies, these interventions normalized reproductive hormones, restored estrous cyclicity and fertility, reduced ovarian cystic changes, and lowered inflammatory markers (TNF-α, IL-6, IL-10, IL-17, IL-18) without observable toxicity. Nevertheless, clinical translation remains pending due to the absence of long-term safety data and well-structured human clinical trials. Future research should prioritize mechanistic validation, long-term toxicological assessment, formulation standardization, and rigorously designed clinical trials.
Indexed as
Identifiers
42133067What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.